- Home
- PLUR vs RNXT Comparison
PLUR vs RNXT Comparison
Compare PLUR & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- RNXT
- Stock Information
- Founded
- PLUR 2001
- RNXT 2012
- Country
- PLUR Israel
- RNXT United States
- Employees
- PLUR N/A
- RNXT N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- RNXT Health Care
- Exchange
- PLUR Nasdaq
- RNXT Nasdaq
- Market Cap
- PLUR 41.9M
- RNXT 44.6M
- IPO Year
- PLUR N/A
- RNXT 2021
- Fundamental
- Price
- PLUR $5.88
- RNXT $1.36
- Analyst Decision
- PLUR Strong Buy
- RNXT Strong Buy
- Analyst Count
- PLUR 1
- RNXT 2
- Target Price
- PLUR $12.00
- RNXT $7.25
- AVG Volume (30 Days)
- PLUR 62.9K
- RNXT 147.2K
- Earning Date
- PLUR 05-13-2025
- RNXT 08-12-2025
- Dividend Yield
- PLUR N/A
- RNXT N/A
- EPS Growth
- PLUR N/A
- RNXT N/A
- EPS
- PLUR N/A
- RNXT N/A
- Revenue
- PLUR $1,034,000.00
- RNXT $240,000.00
- Revenue This Year
- PLUR $472.39
- RNXT $3,186.05
- Revenue Next Year
- PLUR $254.29
- RNXT $291.93
- P/E Ratio
- PLUR N/A
- RNXT N/A
- Revenue Growth
- PLUR 203.23
- RNXT N/A
- 52 Week Low
- PLUR $3.33
- RNXT $0.75
- 52 Week High
- PLUR $7.13
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- PLUR 66.26
- RNXT 55.76
- Support Level
- PLUR $4.61
- RNXT $1.27
- Resistance Level
- PLUR $5.40
- RNXT $1.42
- Average True Range (ATR)
- PLUR 0.55
- RNXT 0.07
- MACD
- PLUR 0.13
- RNXT -0.02
- Stochastic Oscillator
- PLUR 91.46
- RNXT 62.50
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.